Drug Profile
Research programme: DNA vaccines - Inovio
Alternative Names: Chikungunya virus DNA vaccine - Inovio; CHIKV vaccine - Inovio; Cytomegalovirus DNA vaccine - Inovio; dMab HIV - Inovio; DNA vaccine against HIV clade C - Inovio; INO 5400; MAGE-A DNA vaccine; Malaria vaccine - Inovio; Prostate-cancer DNA vaccines - Inovio; Smallpox vaccine - Inovio; SynCon WT1 cancer immunotherapyLatest Information Update: 11 Jun 2021
Price :
$50
*
At a glance
- Originator Inovio Pharmaceuticals
- Developer Drexel University College of Medicine; Inovio Pharmaceuticals; Walter Reed Army Institute of Research; Wistar Institute
- Class AIDS vaccines; Bacterial vaccines; Cancer vaccines; DNA vaccines; Hepatitis C vaccines; Parasitic vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Smallpox
Highest Development Phases
- Preclinical Prostate cancer
- Discontinued Cancer; Chikungunya virus infections; Clostridium difficile infections; Cytomegalovirus infections; Human papillomavirus infections; Malaria; Malignant melanoma; Smallpox; Tuberculosis
Most Recent Events
- 10 Apr 2021 Preclinical trials in Prostate cancer in USA (Parenteral) prior to April 2021
- 10 Apr 2021 Pharmacodynamics data from preclinical studies in prostate cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 09 Apr 2021 Early research in Prostate cancer in USA (Parenteral) prior to April 2021